ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Oxaliplatin

Also written as “oxaliplatin”, “Oxaliplatin (SR96669)” and “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab”.

Its studies are mostly in Colorectal Neoplasms · Stomach Neoplasms · Pancreatic Neoplasms · Rectal Neoplasms · Carcinoma, Hepatocellular, led by 9 companies.

Drug pageOxaliplatin: every studyMany companies study it; this page follows only the 66 they lead. All 854 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 10, 200566 company-led studies, 2 open or runningNext primary completion: Mar 22, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofiits history only360 open or runningphase 4since Aug 10, 2005Jan 6, 2001none ahead
Hoffmann-La Roche201 open or runningphase 4since Dec 18, 2007Sep 15, 2003Mar 22, 2027phase 1 · NCT06624085
Prologue Research Internationalits history only30 open or runningphase 3since Jun 5, 2003May 6, 2001none ahead
Pfizerits history only21 open or runningphase 3since Oct 5, 2020Nov 6, 2007none ahead
Criteriumits history only10 open or runningphase 2since Sep 24, 2019Sep 24, 2019none ahead
GlaxoSmithKlineits history only10 open or runningphase 1since Sep 27, 2007Sep 27, 2007none ahead
Nang Kuang Pharmaceuticalits history only10 open or runningphase 2since Mar 28, 2011Mar 28, 2011none ahead
NovoCureits history only10 open or runningno phasesince Feb 20, 2020Feb 20, 2020none ahead
Sirtex Medicalits history only10 open or runningphase 3since Aug 13, 2008Aug 13, 2008none ahead

Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Johnson & Johnson, Ono Pharmaceutical, Merck KGaA, Darmstadt, Germany, Eli Lilly, Parexel, Halozyme Therapeutics, BioLineRx, AbbVie, Zai Lab, Amgen, Bristol-Myers Squibb, Regeneron Pharmaceuticals and Yakult Honsha.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Sep 15, 2003.

  1. Dec 18, 2007Phase 4 study in Colorectal NeoplasmsNCT00577031 · 205 enrolled · Italy
  2. Feb 18, 2008Phase 3 study in Colorectal NeoplasmsNCT00623805 · 123 enrolled · Turkey
  3. Mar 19, 2008Phase 2 study in Colorectal NeoplasmsNCT00642603 · 41 enrolled · United States
  4. Jun 17, 2008Phase 2 study in Colorectal NeoplasmsNCT00700570 · 45 enrolled · Taiwan
  5. Feb 26, 2010Phase 2 study in Colorectal NeoplasmsNCT01077739 · 75 enrolled · Belgium
  6. May 25, 2010Phase 2 study in Stomach NeoplasmsNCT01130337 · 36 enrolled · Spain
  7. Jun 1, 2010Phase 2 study in Colorectal NeoplasmsNCT01135498 · 90 enrolled · Spain
  8. Jul 7, 2010Phase 2 study in Colorectal NeoplasmsNCT01159171 · 50 enrolled · Italy
  9. Dec 10, 2012Phase 2 study in Stomach NeoplasmsNCT01748773 · 34 enrolled · Turkey
  10. May 15, 2014Phase 2 study in Colorectal NeoplasmsNCT02141295 · 197 enrolled · United States, Australia, Austria and more
  11. Sep 24, 2015Phase 3 study in Stomach NeoplasmsNCT02560974 · 1,035 enrolled · China, Korea, Republic of, Taiwan
  12. Feb 25, 2016Phase 2 study in Rectal NeoplasmsNCT02694718 · 60 enrolled · Switzerland
  13. Sep 11, 2017Phase 2 study in Esophageal NeoplasmsNCT03281369 · 219 enrolled · United States, Australia, Israel and more
  14. Oct 1, 2024Phase 1 study in LymphomaNCT06624085 · 50 enrolled · United States, Puerto Rico

Ahead

  1. Mar 22, 2027Primary completion: phase 1 study in LymphomaNCT06624085

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 20 Hoffmann-La Roche leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06624085Lymphoma · United States, Puerto Rico1Active, not recruitingMar 22, 202750
NCT03281369Esophageal Neoplasms · United States, Australia, Israel and more2TerminatedOct 9, 2025219
NCT02694718Rectal Neoplasms · Switzerland2CompletedAug 200660
NCT02560974Stomach Neoplasms · China, Korea, Republic of, Taiwan3CompletedNov 20121,035
NCT02141295Colorectal Neoplasms · United States, Australia, Austria and more2TerminatedJul 29, 2016197
NCT01748773Stomach Neoplasms · Turkey2CompletedAug 21, 201534
NCT01159171Colorectal Neoplasms · Italy2CompletedJul 201050
NCT01135498Colorectal Neoplasms · Spain2CompletedApr 201090
NCT01130337Stomach Neoplasms · Spain2CompletedJun 201436
NCT01077739Colorectal Neoplasms · Belgium2CompletedJan 201275
NCT00700570Colorectal Neoplasms · Taiwan2CompletedNov 201145
NCT00642603Colorectal Neoplasms · United States2TerminatedMar 200941
NCT00623805Colorectal Neoplasms · Turkey3CompletedMay 2012123
NCT00577031Colorectal Neoplasms · Italy4CompletedAug 2011205
NCT00439426Nasopharyngeal Neoplasms · Morocco2CompletedSep 200925
NCT00436241Stomach Neoplasms · Taiwan2CompletedNov 201045
NCT00353262Colorectal Neoplasms · Canada1CompletedSep 200636
NCT00345761Colorectal Neoplasms · Japan2CompletedOct 200864
NCT00069121Colorectal Neoplasms · United States, Australia, Belgium and more3CompletedApr 21, 20111,886
NCT00069095Colorectal Neoplasms · United States, Australia, Austria and more3CompletedJan 20062,035

How it is read

Names in the registry

  • “Oxaliplatin”, 51 entries
  • “oxaliplatin”, 20 entries
  • “Oxaliplatin (SR96669)”, 3 entries
  • “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab”, 3 entries
  • “OXALIPLATIN”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.